madamemagoo
Junior Member
don't shoot mandy magoo!
Posts: 70
|
Post by madamemagoo on Sept 30, 2015 12:31:26 GMT
Anavex (AVXL) should be wild ride next few weeks. Whether you believe in the science or not should be a good trading play.
|
|
|
madamemagoo
Junior Member
don't shoot mandy magoo!
Posts: 70
|
Post by madamemagoo on Oct 7, 2015 15:18:34 GMT
Last 4 trading days... up 12% up 18% down 25% - smear article, R/S announced up ?
|
|
|
Post by JHam on Nov 3, 2015 3:13:44 GMT
|
|
madamemagoo
Junior Member
don't shoot mandy magoo!
Posts: 70
|
Post by madamemagoo on Nov 3, 2015 11:57:35 GMT
The Lincoln Park deal was actually viewed favorably...it's a different reality in AVXL-land. Might I add that the Kool-Aid is delightful!
|
|
|
Post by JHam on Nov 3, 2015 12:14:19 GMT
The Lincoln Park deal was actually viewed favorably...it's a different reality in AVXL-land. Might I add that the Kool-Aid is delightful! Lol, it was viewed favorably by the kool-aide drinkers who really don't understand just how bad these LP deals are for shareholders. I bet none of them even looked at the actual agreement itself. OCAT shareholders also thought their LP deal was great until they finally started to understand it. It makes no sense at all imo that a company ready for the big time inks that kind of a deal. Congrats if you made some money though, nothing wrong with that.
|
|
|
Post by JHam on Nov 3, 2015 13:27:28 GMT
|
|
|
Post by JHam on Nov 5, 2015 21:42:34 GMT
|
|
madamemagoo
Junior Member
don't shoot mandy magoo!
Posts: 70
|
Post by madamemagoo on Nov 5, 2015 23:12:11 GMT
I'm holding...on...
|
|
|
Post by JHam on Nov 5, 2015 23:16:20 GMT
I'm holding...on... Seriously? You have guts I'll give you that...
|
|
|
Post by JHam on Nov 6, 2015 15:54:05 GMT
Looks like people are starting to realize that the data is a joke and that the pump is over. Lincoln probably also has something to do with it.
|
|
madamemagoo
Junior Member
don't shoot mandy magoo!
Posts: 70
|
Post by madamemagoo on Nov 7, 2015 14:55:04 GMT
|
|
|
Post by JHam on Nov 9, 2015 14:31:20 GMT
|
|
|
Post by JHam on Nov 9, 2015 14:33:29 GMT
|
|
|
Post by furbush87 on Nov 9, 2015 15:32:46 GMT
Look, 6 months ago AVXL was trading at .38 or so (about a $1.20is pre R/S), then it ran up to $14 or so (not paying that close of attention) that was a totally unwarranted move totally based on a Phase 2 trial that has similar results to drugs being worked on by big name pharmas (don't remember which one read the studies months ago). Only retail could move it up that fast, and now those retailers are going to loose out on the gains. This will most likely drop more and finally find a balance around $4 which is more warranted. It is not just about the science, it is also about competition, stage of development, and the fact that it only has a 50/50 shot of being successful.
|
|
|
Post by JHam on Nov 9, 2015 17:14:45 GMT
Look, 6 months ago AVXL was trading at .38 or so (about a $1.20is pre R/S), then it ran up to $14 or so (not paying that close of attention) that was a totally unwarranted move totally based on a Phase 2 trial that has similar results to drugs being worked on by big name pharmas (don't remember which one read the studies months ago). Only retail could move it up that fast, and now those retailers are going to loose out on the gains. This will most likely drop more and finally find a balance around $4 which is more warranted. It is not just about the science, it is also about competition, stage of development, and the fact that it only has a 50/50 shot of being successful. Yes but it can't even be compared to the other studies because this one is is so small and only 5 weeks! From the article which I have been saying from the beginning about this so called "data"...: No, the data do not show that at all. Here's why:
In the clinical trial, Anavex took a handful of Alzheimer's patients and treated all of them with a drug they were told might help improve their memory and cognition. After taking Anavex 2-73 for just five weeks, the patients were given a battery of tests to measure memory and cognition. Not surprisingly, the memory and cognition of the patients improved just a little bit.
To Anavex and its stock promoters, this was success. To everyone else, it's just another classic example of a placebo effect. The handful of Alzheimer's patients in the Anavex study improved over a short period of time because they were easily convinced the drug they were taking would help them.
"The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%," said Dr. Adam Kline, an Alzheimer's disease researcher who reviewed the Anavex 2-73 data presented Saturday.
The only way to produce credible data in Alzheimer's is to conduct randomized, double-blind, placebo-controlled studies. One group of patients is randomized to receive a drug, the other group of patients received a placebo.
Neither the patients nor their doctors know which arm of the study they're in. These studies need to run 52 weeks, not five weeks, because it takes that long to detect meaningful changes in memory, cognition and functions of daily living of patients.
The small, short, single-arm, open-label study run by Anavex met none of these scientific criteria, making the results presented Saturday clinically meaningless.
|
|
|
Post by furbush87 on Nov 9, 2015 21:15:23 GMT
|
|
madamemagoo
Junior Member
don't shoot mandy magoo!
Posts: 70
|
Post by madamemagoo on Nov 9, 2015 23:21:20 GMT
I bought in @.51-1.25 pre-split...so I'm okay, but keep thinking coulda..woulda..shoulda...
|
|
|
Post by furbush87 on Nov 10, 2015 1:58:41 GMT
I bought in @.51-1.25 pre-split...so I'm okay, but keep thinking coulda..woulda..shoulda... Be careful, because you know that when AF starts after a company, unless they have something solid he brings them down. I see nothing solid in AVXL. You probably should walk with your profits. But your decision.
|
|
|
Post by JHam on Nov 10, 2015 2:07:22 GMT
I bought in @.51-1.25 pre-split...so I'm okay, but keep thinking coulda..woulda..shoulda... Be careful, because you know that when AF starts after a company, unless they have something solid he brings them down. I see nothing solid in AVXL. You probably should walk with your profits. But your decision. I am not telling anyone what to do with their own money, but the writing was on the wall with this one from the get go. There was never any characteristics of this being a good investment decision (crazy amounts of outstanding warrants, no cash, debt, trial data that was meaningless...). Obvious promoted/orchestrated pump.
|
|